| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peritoneal Neoplasms | 8 | 2022 | 821 | 2.040 |
Why?
|
| Uterine Cervical Neoplasms | 17 | 2023 | 1833 | 1.780 |
Why?
|
| Carcinoma, Neuroendocrine | 13 | 2023 | 716 | 1.730 |
Why?
|
| Ovarian Neoplasms | 18 | 2023 | 4638 | 1.600 |
Why?
|
| Endometrial Neoplasms | 14 | 2023 | 1341 | 1.480 |
Why?
|
| Carcinoma, Endometrioid | 5 | 2023 | 323 | 1.080 |
Why?
|
| Asbestos | 1 | 2022 | 35 | 0.860 |
Why?
|
| Cystadenocarcinoma, Serous | 4 | 2022 | 486 | 0.850 |
Why?
|
| PAX8 Transcription Factor | 3 | 2022 | 55 | 0.820 |
Why?
|
| Immunohistochemistry | 23 | 2022 | 7548 | 0.790 |
Why?
|
| Cervix Uteri | 8 | 2023 | 253 | 0.740 |
Why?
|
| Endometriosis | 2 | 2023 | 214 | 0.720 |
Why?
|
| Biomarkers, Tumor | 19 | 2022 | 10331 | 0.720 |
Why?
|
| Carcinoma | 7 | 2023 | 2578 | 0.700 |
Why?
|
| Hysterectomy | 7 | 2023 | 611 | 0.690 |
Why?
|
| Mesothelioma | 1 | 2022 | 544 | 0.590 |
Why?
|
| Teratoma | 3 | 2021 | 236 | 0.560 |
Why?
|
| SMARCB1 Protein | 1 | 2016 | 109 | 0.560 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2020 | 436 | 0.560 |
Why?
|
| Diagnosis, Differential | 16 | 2022 | 4744 | 0.540 |
Why?
|
| Adenocarcinoma | 9 | 2023 | 7789 | 0.540 |
Why?
|
| Fallopian Tube Neoplasms | 3 | 2022 | 153 | 0.540 |
Why?
|
| Pathology, Molecular | 1 | 2016 | 128 | 0.510 |
Why?
|
| Carcinoma, Papillary | 3 | 2012 | 584 | 0.500 |
Why?
|
| DNA Helicases | 1 | 2016 | 434 | 0.480 |
Why?
|
| Keratins | 3 | 2004 | 330 | 0.470 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2016 | 565 | 0.460 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 332 | 0.460 |
Why?
|
| Female | 62 | 2023 | 141928 | 0.450 |
Why?
|
| PAX5 Transcription Factor | 1 | 2013 | 45 | 0.450 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 2013 | 57 | 0.440 |
Why?
|
| Carcinoma, Merkel Cell | 2 | 2021 | 155 | 0.440 |
Why?
|
| Immunophenotyping | 2 | 2016 | 1681 | 0.430 |
Why?
|
| Vulvar Neoplasms | 3 | 2021 | 236 | 0.430 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2008 | 1039 | 0.420 |
Why?
|
| Pseudolymphoma | 1 | 2011 | 22 | 0.410 |
Why?
|
| Uterine Cervical Diseases | 1 | 2011 | 25 | 0.410 |
Why?
|
| Lymphoproliferative Disorders | 3 | 2003 | 366 | 0.410 |
Why?
|
| Endodermal Sinus Tumor | 2 | 2017 | 47 | 0.400 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2012 | 551 | 0.400 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2016 | 519 | 0.390 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2011 | 2232 | 0.390 |
Why?
|
| Duodenitis | 1 | 2011 | 15 | 0.390 |
Why?
|
| Adult | 40 | 2023 | 77950 | 0.380 |
Why?
|
| Humans | 79 | 2023 | 261506 | 0.380 |
Why?
|
| Middle Aged | 39 | 2023 | 86204 | 0.350 |
Why?
|
| Syndecan-1 | 2 | 2008 | 52 | 0.350 |
Why?
|
| Neoplasms, Plasma Cell | 1 | 2008 | 24 | 0.330 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2013 | 406 | 0.310 |
Why?
|
| Stomach | 1 | 2011 | 387 | 0.310 |
Why?
|
| Neoadjuvant Therapy | 3 | 2021 | 4975 | 0.300 |
Why?
|
| Aged | 28 | 2023 | 70117 | 0.300 |
Why?
|
| Nuclear Proteins | 2 | 2023 | 3343 | 0.280 |
Why?
|
| Carcinoma, Small Cell | 2 | 2021 | 408 | 0.270 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2021 | 328 | 0.270 |
Why?
|
| Endometrium | 4 | 2020 | 470 | 0.260 |
Why?
|
| Chromosome Aberrations | 2 | 2011 | 1960 | 0.250 |
Why?
|
| Mucin-1 | 1 | 2004 | 127 | 0.240 |
Why?
|
| Young Adult | 13 | 2023 | 21445 | 0.240 |
Why?
|
| Neoplasms, Second Primary | 3 | 2023 | 1350 | 0.240 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2004 | 178 | 0.230 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2008 | 502 | 0.230 |
Why?
|
| Predictive Value of Tests | 6 | 2022 | 4892 | 0.230 |
Why?
|
| Kidney Neoplasms | 2 | 2023 | 3022 | 0.230 |
Why?
|
| Mesonephroma | 1 | 2023 | 17 | 0.230 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2016 | 341 | 0.230 |
Why?
|
| Neoplasm Staging | 12 | 2023 | 13658 | 0.230 |
Why?
|
| Transcription Factors | 2 | 2016 | 5270 | 0.220 |
Why?
|
| Viral Matrix Proteins | 1 | 2003 | 201 | 0.220 |
Why?
|
| CDX2 Transcription Factor | 1 | 2022 | 37 | 0.210 |
Why?
|
| Retrospective Studies | 19 | 2023 | 37905 | 0.210 |
Why?
|
| Dementia, Multi-Infarct | 1 | 2002 | 2 | 0.210 |
Why?
|
| Neoplasms, Connective Tissue | 1 | 2022 | 20 | 0.210 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2022 | 178 | 0.210 |
Why?
|
| Epithelioid Cells | 1 | 2022 | 43 | 0.200 |
Why?
|
| Lung Transplantation | 2 | 2004 | 359 | 0.200 |
Why?
|
| Thyroid Neoplasms | 2 | 2012 | 1866 | 0.200 |
Why?
|
| Conservative Treatment | 1 | 2021 | 58 | 0.200 |
Why?
|
| Peritoneum | 1 | 2022 | 150 | 0.200 |
Why?
|
| Paget Disease, Extramammary | 1 | 2001 | 55 | 0.190 |
Why?
|
| Carcinoma, Large Cell | 1 | 2021 | 94 | 0.190 |
Why?
|
| Myofibroblasts | 1 | 2022 | 133 | 0.190 |
Why?
|
| Hirschsprung Disease | 2 | 2011 | 46 | 0.190 |
Why?
|
| Aged, 80 and over | 14 | 2023 | 29902 | 0.190 |
Why?
|
| Cysts | 1 | 2022 | 197 | 0.190 |
Why?
|
| Anal Canal | 1 | 2001 | 238 | 0.190 |
Why?
|
| Wolffian Ducts | 1 | 2020 | 24 | 0.180 |
Why?
|
| Biopsy | 6 | 2022 | 3443 | 0.180 |
Why?
|
| Homozygote | 1 | 2022 | 717 | 0.180 |
Why?
|
| Ovary | 2 | 2020 | 668 | 0.180 |
Why?
|
| Pathology, Clinical | 1 | 2021 | 152 | 0.180 |
Why?
|
| Endometrial Hyperplasia | 1 | 2020 | 112 | 0.170 |
Why?
|
| Education, Distance | 1 | 2021 | 93 | 0.170 |
Why?
|
| Keratin-7 | 3 | 2004 | 52 | 0.170 |
Why?
|
| RNA, Viral | 3 | 2011 | 671 | 0.170 |
Why?
|
| Sequence Deletion | 1 | 2022 | 875 | 0.170 |
Why?
|
| Neoplasm Grading | 5 | 2021 | 1742 | 0.170 |
Why?
|
| Biopsy, Fine-Needle | 4 | 2010 | 690 | 0.160 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2011 | 2326 | 0.160 |
Why?
|
| Perineum | 1 | 2018 | 107 | 0.160 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2008 | 1664 | 0.160 |
Why?
|
| Frozen Sections | 1 | 2018 | 105 | 0.160 |
Why?
|
| Multiple Myeloma | 2 | 2008 | 2138 | 0.150 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2022 | 475 | 0.150 |
Why?
|
| Microsatellite Instability | 2 | 2016 | 400 | 0.150 |
Why?
|
| Adolescent | 10 | 2022 | 31252 | 0.150 |
Why?
|
| Uterine Neoplasms | 1 | 2022 | 545 | 0.150 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2018 | 115 | 0.150 |
Why?
|
| Pathology | 1 | 2018 | 101 | 0.150 |
Why?
|
| Neuroendocrine Tumors | 1 | 2023 | 634 | 0.150 |
Why?
|
| Registries | 3 | 2023 | 2170 | 0.150 |
Why?
|
| Carcinosarcoma | 1 | 2018 | 146 | 0.140 |
Why?
|
| Bartholin's Glands | 1 | 2016 | 5 | 0.140 |
Why?
|
| Intermediate Filament Proteins | 2 | 2010 | 81 | 0.140 |
Why?
|
| NF-kappa B | 1 | 2003 | 1549 | 0.140 |
Why?
|
| Germ-Line Mutation | 1 | 2022 | 1046 | 0.140 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 4654 | 0.140 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2008 | 2390 | 0.140 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2020 | 469 | 0.140 |
Why?
|
| B-Lymphocytes | 3 | 2011 | 1294 | 0.140 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2008 | 2027 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2023 | 10035 | 0.140 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 479 | 0.140 |
Why?
|
| Rhabdoid Tumor | 1 | 2016 | 110 | 0.140 |
Why?
|
| Urogenital Neoplasms | 1 | 2017 | 108 | 0.140 |
Why?
|
| Gynecology | 1 | 2018 | 217 | 0.140 |
Why?
|
| Male | 18 | 2021 | 123000 | 0.130 |
Why?
|
| Myometrium | 1 | 2015 | 79 | 0.130 |
Why?
|
| Curriculum | 1 | 2021 | 860 | 0.130 |
Why?
|
| Proteins | 1 | 2003 | 1963 | 0.130 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2008 | 2341 | 0.130 |
Why?
|
| Antigens, CD34 | 1 | 2016 | 593 | 0.130 |
Why?
|
| Lung Neoplasms | 4 | 2020 | 11538 | 0.120 |
Why?
|
| DNA Mismatch Repair | 1 | 2016 | 268 | 0.120 |
Why?
|
| Herpesvirus 4, Human | 3 | 2011 | 966 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2022 | 9244 | 0.120 |
Why?
|
| Phenotype | 2 | 2016 | 6295 | 0.120 |
Why?
|
| Multimodal Imaging | 1 | 2018 | 550 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2021 | 3552 | 0.120 |
Why?
|
| DNA Copy Number Variations | 1 | 2020 | 1516 | 0.110 |
Why?
|
| Endoscopy | 1 | 2016 | 479 | 0.110 |
Why?
|
| Antibodies | 1 | 2016 | 838 | 0.110 |
Why?
|
| Rectal Neoplasms | 1 | 2001 | 1202 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2021 | 5437 | 0.110 |
Why?
|
| Calcinosis | 1 | 2016 | 423 | 0.110 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2016 | 592 | 0.110 |
Why?
|
| Sensitivity and Specificity | 5 | 2023 | 4971 | 0.110 |
Why?
|
| Contrast Media | 2 | 2016 | 1472 | 0.110 |
Why?
|
| Liver Neoplasms | 1 | 2008 | 4557 | 0.100 |
Why?
|
| S100 Calcium Binding Protein G | 1 | 2011 | 50 | 0.100 |
Why?
|
| Survival Rate | 5 | 2022 | 12221 | 0.100 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 925 | 0.100 |
Why?
|
| Treatment Outcome | 7 | 2022 | 32848 | 0.100 |
Why?
|
| Androgen Antagonists | 1 | 2013 | 411 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2023 | 7551 | 0.100 |
Why?
|
| In Situ Hybridization | 2 | 2003 | 1037 | 0.100 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2011 | 247 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2018 | 1162 | 0.090 |
Why?
|
| Meningioma | 1 | 2013 | 289 | 0.090 |
Why?
|
| Organ Transplantation | 2 | 2003 | 191 | 0.090 |
Why?
|
| Urinalysis | 1 | 2011 | 84 | 0.090 |
Why?
|
| Paraffin Embedding | 1 | 2011 | 226 | 0.090 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2011 | 297 | 0.090 |
Why?
|
| Prognosis | 5 | 2023 | 21713 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2010 | 135 | 0.090 |
Why?
|
| Tracheal Neoplasms | 1 | 2010 | 42 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2011 | 234 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2011 | 290 | 0.090 |
Why?
|
| S100 Proteins | 1 | 2010 | 181 | 0.090 |
Why?
|
| Ameloblastoma | 1 | 2009 | 17 | 0.090 |
Why?
|
| Cyclin D1 | 1 | 2012 | 576 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 4 | 2020 | 3981 | 0.090 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 14889 | 0.090 |
Why?
|
| Trisomy | 1 | 2010 | 231 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2006 | 1493 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2011 | 311 | 0.090 |
Why?
|
| Metaplasia | 1 | 2011 | 383 | 0.090 |
Why?
|
| Genomics | 1 | 2020 | 2738 | 0.090 |
Why?
|
| Osteonectin | 1 | 2009 | 53 | 0.090 |
Why?
|
| Mandibular Neoplasms | 1 | 2009 | 76 | 0.080 |
Why?
|
| Neural Plate | 1 | 2008 | 10 | 0.080 |
Why?
|
| Bone Marrow Examination | 1 | 2008 | 153 | 0.080 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 840 | 0.080 |
Why?
|
| Precision Medicine | 1 | 2016 | 1154 | 0.080 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 15694 | 0.080 |
Why?
|
| Abdominal Pain | 1 | 2011 | 369 | 0.080 |
Why?
|
| Herpesvirus 8, Human | 1 | 2008 | 102 | 0.080 |
Why?
|
| Child, Preschool | 3 | 2021 | 16273 | 0.080 |
Why?
|
| Mastocytosis, Systemic | 1 | 2008 | 110 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2011 | 641 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2013 | 8873 | 0.080 |
Why?
|
| Chemoradiotherapy | 1 | 2016 | 1946 | 0.080 |
Why?
|
| Membrane Glycoproteins | 2 | 2010 | 1073 | 0.070 |
Why?
|
| HIV | 1 | 2008 | 229 | 0.070 |
Why?
|
| HIV Infections | 2 | 2011 | 2134 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2021 | 3890 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2020 | 3341 | 0.070 |
Why?
|
| Thyroid Gland | 1 | 2008 | 355 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2008 | 829 | 0.070 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2020 | 521 | 0.070 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2008 | 362 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 2 | 2011 | 1491 | 0.070 |
Why?
|
| Cisplatin | 2 | 2023 | 2432 | 0.070 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2010 | 387 | 0.070 |
Why?
|
| Child | 5 | 2021 | 29154 | 0.070 |
Why?
|
| Lymph Node Excision | 3 | 2018 | 1959 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 3203 | 0.070 |
Why?
|
| Lewis X Antigen | 1 | 2004 | 46 | 0.060 |
Why?
|
| Colon | 3 | 2016 | 670 | 0.060 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 3578 | 0.060 |
Why?
|
| Repressor Proteins | 2 | 2023 | 1664 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 15862 | 0.060 |
Why?
|
| Thiazoles | 1 | 2008 | 726 | 0.060 |
Why?
|
| Glioma | 1 | 2015 | 1963 | 0.060 |
Why?
|
| WT1 Proteins | 1 | 2004 | 106 | 0.060 |
Why?
|
| TNF Receptor-Associated Factor 1 | 1 | 2003 | 8 | 0.060 |
Why?
|
| TNF Receptor-Associated Factor 3 | 1 | 2003 | 22 | 0.060 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2003 | 39 | 0.060 |
Why?
|
| alpha-Fetoproteins | 1 | 2004 | 237 | 0.060 |
Why?
|
| Mutation | 3 | 2020 | 15179 | 0.060 |
Why?
|
| Appendiceal Neoplasms | 1 | 2006 | 234 | 0.060 |
Why?
|
| Disease-Free Survival | 3 | 2023 | 10001 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2021 | 2292 | 0.060 |
Why?
|
| SOXF Transcription Factors | 1 | 2023 | 34 | 0.060 |
Why?
|
| Lymphoma | 1 | 2011 | 1467 | 0.060 |
Why?
|
| Early Detection of Cancer | 1 | 2011 | 1258 | 0.060 |
Why?
|
| Risk Factors | 2 | 2020 | 17523 | 0.060 |
Why?
|
| CD79 Antigens | 1 | 2002 | 7 | 0.050 |
Why?
|
| Leukosialin | 1 | 2002 | 16 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2004 | 479 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 5539 | 0.050 |
Why?
|
| Sialoglycoproteins | 1 | 2002 | 151 | 0.050 |
Why?
|
| Topotecan | 1 | 2022 | 239 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2002 | 182 | 0.050 |
Why?
|
| Germinal Center | 1 | 2002 | 161 | 0.050 |
Why?
|
| Biomarkers | 2 | 2011 | 5047 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2004 | 842 | 0.050 |
Why?
|
| Polyploidy | 1 | 2022 | 73 | 0.050 |
Why?
|
| Keratin-20 | 1 | 2001 | 44 | 0.050 |
Why?
|
| Antigens, CD20 | 1 | 2002 | 206 | 0.050 |
Why?
|
| Conization | 1 | 2021 | 36 | 0.050 |
Why?
|
| Hemorrhoids | 1 | 2001 | 13 | 0.050 |
Why?
|
| Laparoscopy | 2 | 2021 | 1225 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 3101 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2020 | 1331 | 0.050 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2003 | 181 | 0.050 |
Why?
|
| Speech Disorders | 1 | 2002 | 91 | 0.050 |
Why?
|
| Etoposide | 1 | 2023 | 870 | 0.050 |
Why?
|
| Merkel cell polyomavirus | 1 | 2021 | 30 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 6009 | 0.050 |
Why?
|
| Ki-1 Antigen | 1 | 2002 | 182 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2010 | 3033 | 0.050 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2002 | 171 | 0.050 |
Why?
|
| Virtual Reality | 1 | 2021 | 34 | 0.050 |
Why?
|
| Staining and Labeling | 1 | 2022 | 429 | 0.050 |
Why?
|
| Prophylactic Surgical Procedures | 1 | 2020 | 23 | 0.050 |
Why?
|
| Salpingo-oophorectomy | 1 | 2020 | 50 | 0.050 |
Why?
|
| Hospitals, Teaching | 1 | 2021 | 120 | 0.050 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2020 | 43 | 0.050 |
Why?
|
| Premenopause | 1 | 2020 | 131 | 0.050 |
Why?
|
| Chromogranins | 1 | 2020 | 84 | 0.050 |
Why?
|
| Carboplatin | 1 | 2023 | 823 | 0.050 |
Why?
|
| Computer-Assisted Instruction | 1 | 2021 | 81 | 0.050 |
Why?
|
| Disease Progression | 2 | 2022 | 6682 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2020 | 9180 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2010 | 6915 | 0.040 |
Why?
|
| Fallopian Tubes | 1 | 2020 | 119 | 0.040 |
Why?
|
| Receptors, Estrogen | 2 | 2006 | 2086 | 0.040 |
Why?
|
| Memory Disorders | 1 | 2002 | 295 | 0.040 |
Why?
|
| Bevacizumab | 1 | 2022 | 938 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2021 | 12873 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2009 | 2669 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2003 | 1581 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2023 | 1301 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2023 | 833 | 0.040 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2023 | 1226 | 0.040 |
Why?
|
| Lymphoma, B-Cell | 1 | 2004 | 895 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2002 | 1385 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 7702 | 0.040 |
Why?
|
| Antineoplastic Agents | 3 | 2021 | 14289 | 0.040 |
Why?
|
| Time Factors | 3 | 2020 | 12926 | 0.040 |
Why?
|
| Microspheres | 1 | 2016 | 210 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2008 | 3518 | 0.030 |
Why?
|
| Paired Box Transcription Factors | 1 | 2016 | 134 | 0.030 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2003 | 962 | 0.030 |
Why?
|
| Risk | 1 | 2020 | 1972 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2022 | 1996 | 0.030 |
Why?
|
| Neoplasm Proteins | 2 | 2004 | 3230 | 0.030 |
Why?
|
| Sentinel Lymph Node | 1 | 2018 | 216 | 0.030 |
Why?
|
| Alleles | 1 | 2021 | 2437 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2023 | 2173 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 672 | 0.030 |
Why?
|
| Hospitals | 1 | 2018 | 485 | 0.030 |
Why?
|
| Cranial Irradiation | 1 | 2016 | 315 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2018 | 627 | 0.030 |
Why?
|
| Animals | 2 | 2016 | 59536 | 0.030 |
Why?
|
| Epithelium | 1 | 2016 | 720 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2021 | 1863 | 0.030 |
Why?
|
| Lymph Nodes | 2 | 2018 | 2967 | 0.030 |
Why?
|
| Receptors, LHRH | 1 | 2013 | 41 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 2001 | 1390 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 2316 | 0.030 |
Why?
|
| Gadolinium DTPA | 1 | 2013 | 172 | 0.030 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2016 | 356 | 0.030 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2004 | 275 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 2291 | 0.030 |
Why?
|
| Ganglia | 1 | 2011 | 20 | 0.030 |
Why?
|
| Calbindin 2 | 1 | 2011 | 40 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2016 | 1090 | 0.030 |
Why?
|
| Observer Variation | 1 | 2013 | 671 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2013 | 666 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 1559 | 0.020 |
Why?
|
| Peripherins | 1 | 2010 | 4 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2008 | 3536 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2018 | 929 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 2283 | 0.020 |
Why?
|
| Texas | 1 | 2021 | 6311 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2021 | 1375 | 0.020 |
Why?
|
| Mass Screening | 1 | 2018 | 1509 | 0.020 |
Why?
|
| Lymphatic Diseases | 1 | 2010 | 128 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2013 | 561 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 1678 | 0.020 |
Why?
|
| Apoptosis | 1 | 2003 | 7591 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2016 | 1824 | 0.020 |
Why?
|
| DNA Probes | 1 | 2008 | 217 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 4844 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2009 | 5395 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 5687 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 612 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 2139 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2008 | 568 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2008 | 355 | 0.020 |
Why?
|
| Rectum | 1 | 2010 | 467 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2013 | 1392 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2002 | 5542 | 0.020 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2009 | 310 | 0.020 |
Why?
|
| DNA Primers | 1 | 2008 | 1399 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 6942 | 0.020 |
Why?
|
| Dasatinib | 1 | 2008 | 862 | 0.020 |
Why?
|
| Vimentin | 1 | 2006 | 253 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 4320 | 0.020 |
Why?
|
| Ohio | 1 | 2004 | 113 | 0.020 |
Why?
|
| Infant | 2 | 2010 | 13310 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 8865 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2003 | 2488 | 0.010 |
Why?
|
| Syndecans | 1 | 2002 | 27 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 2003 | 196 | 0.010 |
Why?
|
| Neprilysin | 1 | 2002 | 66 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2002 | 54 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2002 | 125 | 0.010 |
Why?
|
| Azacitidine | 1 | 2009 | 1149 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2003 | 367 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2009 | 1299 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 3639 | 0.010 |
Why?
|
| Remission Induction | 1 | 2008 | 3569 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 2004 | 462 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2002 | 259 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 5112 | 0.010 |
Why?
|
| Protein Array Analysis | 1 | 2003 | 501 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 4849 | 0.010 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2003 | 661 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 2489 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2009 | 6150 | 0.010 |
Why?
|
| Neoplasms | 1 | 2004 | 15193 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2010 | 8223 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 5159 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2002 | 1265 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2013 | 5767 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2009 | 7226 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2003 | 1756 | 0.010 |
Why?
|
| Incidence | 1 | 2004 | 5673 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 4821 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2004 | 14551 | 0.010 |
Why?
|